Navigation Links
Ten Latin American Scientists Named 2008 Pew Fellows in the Biomedical Sciences

Program Supports Development of Strong Scientific Capacity in Latin America

WASHINGTON, June 12 /PRNewswire-USNewswire/ -- The Pew Charitable Trusts and the University of California at San Francisco (UCSF) announced today that 10 promising biomedical scientists have been named 2008 Pew Latin American Fellows in the Biomedical Sciences. Funded by Pew through a grant to UCSF, the highly competitive fellowship program offers talented young Latin American scientists $60,000 for a two-year training period. The award is administered by the sponsoring U.S. institution, which supplements the stipend with at least $5,000 a year and also provides medical benefits for the fellow. Following the two year fellowship, the Program will issue an additional $35,000 award to the sponsoring institution to purchase equipment and supplies for the fellow to establish a laboratory in his or her home country.

"Pew's Latin American Fellows Program gives these exemplary scientists the opportunity to further their knowledge, and it promotes exchange and collaboration between researchers in the United States and Latin America," said Rebecca W. Rimel, President and Chief Executive Officer of The Pew Charitable Trusts.

The Pew Latin American Fellows Program in the Biomedical Sciences was launched in 1991 to help develop a cadre of highly trained Latin American scientists who could stimulate and contribute to the growth of quality biomedical science and foster collaboration between scientists in Latin America and the U.S. Since 1991, the Trusts has invested more than $11 million to fund more than 150 fellows, close to 80 percent of whom have returned to their home countries. Applicants from all Central and South American countries are invited to apply, and selection is made by a distinguished national advisory committee chaired by Dr. Torsten N. Wiesel, president emeritus of Rockefeller University and a 1981 Nobel laureate in physiology or medicine.

The 2008 Pew Latin American Fellows in the Biomedical Sciences are:

Fellow Host Laboratory

Mariano Andres Belluscio, Ph.D., Argentina Rutgers University

Katia Carneiro de Paula, Ph.D., Brazil Forsyth Institute/Harvard

School of Dental Medicine

Mauro Javier Cortez Veliz, Ph.D., Brazil Yale University

Maria de la Paz Fernandez, Ph.D., Argentina Harvard University

Nicolas Frankel, Ph.D., Argentina Princeton University

Paula Licona-Limon, Ph.D., Mexico Yale University

Leticia Irene Llarrull, Ph.D., Argentina University of Notre Dame

Cecilia Martin, Ph.D., Mexico Massachusetts General


Hector Alex Saka, Ph.D., Argentina Duke University

Marcos Sawada Simoes-Costa, Ph.D., Brazil California Institute of


For full biographies and information regarding the fellows' research subjects, please visit

The Pew Charitable Trusts ( is driven by the power of knowledge to solve today's most challenging problems. Pew applies a rigorous, analytical approach to improve public policy, inform the public and stimulate civic life. We partner with a diverse range of donors, public and private organizations and concerned citizens who share our commitment to fact-based solutions and goal-driven investments to improve society.

SOURCE Pew Charitable Trusts
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Oncolytics Biotech Inc. Starts Patient Enrolment in U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
2. Monsantos Industry-Leading Seed Position Creates Accelerated Biotech Trait Opportunity in Latin America
3. Oncolytics Biotech Inc. Announces U.K. Phase II Clinical Trial Investigating REOLYSIN(R) in Combination with Paclitaxel and Carboplatin
4. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
5. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
6. White Paper Details New Techniques for Isolating, Identifying Anaerobic Bacteria and Organisms
7. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Paclitaxel and Carboplatin Trial
8. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Combination REOLYSIN(R) and Carboplatin/Paclitaxel Trial
9. Proteon Therapeutics Receives European Patent Covering New Method of Dilating Arteries and Veins
10. UCT Specialties (Formerly Petrarch) Announces the Release of Their New Product Guides for Silanes, Silicones, Platinum Catalyst and Glass Coatings
11. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
Post Your Comments:
(Date:6/27/2016)... June 27, 2016 /PRNewswire/ - BIOREM Inc. (TSX-V: BRM) ("Biorem" ... by its major shareholders, Clean Technology Fund I, LP ... States based venture capital funds which together ... (on a fully diluted, as converted basis), that they ... their entire equity holdings in Biorem to TUS Holdings ...
(Date:6/27/2016)... Raleigh, NC (PRWEB) , ... June 27, 2016 ... ... a mission to bring innovative medical technologies, services and solutions to the healthcare ... development and implementation of various distribution, manufacturing, sales and marketing strategies that are ...
(Date:6/24/2016)... 24, 2016  Regular discussions on a range of subjects ... the two entities said Poloz. Speaking at a ... , he pointed to the country,s inflation target, which ... "In certain areas ... have common economic goals, why not sit down and address ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
Breaking Biology Technology:
(Date:4/28/2016)... , April 28, 2016 First quarter 2016: ... up 966% compared with the first quarter of 2015 ... SEK 589.1 M (loss: 18.8) and the operating margin was 40% ... 0.32) Cash flow from operations was SEK 249.9 M ... revenue guidance is unchanged, SEK 7,000-8,500 M. The operating ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
Breaking Biology News(10 mins):